

Financial Express, Delhi

Tuesday, 26th July 2011, Page: 6

Width: 5.72 cms Height: 5.55 cms, Ref: pmin.2011-07-26.40.55

Glenmark completes phase I trial of painkiller

Glenmark Pharmaceuticals (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals, said it has successfully completed phase I trials of GRC 15300, a first-in-class TRPV3 inhibitor for treatment of pain. "Glenmark has completed Phase I dosing and analysis of the study data of GRC 15300 in the UK and the drug has been well tolerated with a good pharmacokinetic profile. Plans are in place to initiate clinical proof of concept studies in neuropathic pain," Glenmark said in a press release.